Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Anna Melone"'
Autor:
Larissa Brosi, Thomas K. Villiger, Frank I. Bantleon, Anna Melone, Marie-Eve Überschlag, Daniele Dolce, Cedric Giegelmann, Michael Gerspach, Lorin Dirscherl, Sherin Panikulam, Patrick Romann, Anna Weston, Eric Kübler, Christian-B. Gerhold
Publikováno v:
CHIMIA, Vol 75, Iss 5 (2021)
Serological testing for antibodies directed against SARS-CoV-2 in patients may serve as a diagnostic tool to verify a previous infection and as surrogate for an elicited humoral immune response, ideally conferring immunity after infection or vaccinat
Externí odkaz:
https://doaj.org/article/69e7fe4015df4f13ac4f5683a212ce03
Autor:
Emilia Salvadori, Francesco Galmozzi, Francesca Uda, Carmen Barbato, Eleonora Camilleri, Francesca Cesari, Stefano Chiti, Stefano Diciotti, Samira Donnini, Benedetta Formelli, Silvia Galora, Betti Giusti, Anna Maria Gori, Chiara Marzi, Anna Melone, Damiano Mistri, Francesca Pescini, Giovanni Pracucci, Valentina Rinnoci, Cristina Sarti, Enrico Fainardi, Rossella Marcucci, Anna Poggesi
Publikováno v:
Frontiers in Neurology, Vol 11 (2020)
Background/Objective: Growing evidence suggests a close relationship between motor and cognitive abilities, but possible common underlying mechanisms are not well-established. Atrial fibrillation (AF) is associated with reduced physical performance a
Externí odkaz:
https://doaj.org/article/04cfb1230e734b9ca438eb99341e1f19
Autor:
Thomas Bohnacker, Andrea E. Prota, Florent Beaufils, John E. Burke, Anna Melone, Alison J. Inglis, Denise Rageot, Alexander M. Sele, Vladimir Cmiljanovic, Natasa Cmiljanovic, Katja Bargsten, Amol Aher, Anna Akhmanova, J. Fernando Díaz, Doriano Fabbro, Marketa Zvelebil, Roger L. Williams, Michel O. Steinmetz, Matthias P. Wymann
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Buparlisib/BKM120 is in phase 3 clinical trials as a phosphoinositide 3-kinase (PI3K) inhibitor. Here, Bohnackeret al. combine chemical biology and structural biology approaches to segregate BKM120’s biological actions, and suggest that it causes m
Externí odkaz:
https://doaj.org/article/a5212909a4a7490db4d79600c172c822
Autor:
Anna Poggesi, Carmen Barbato, Francesco Galmozzi, Eleonora Camilleri, Francesca Cesari, Stefano Chiti, Stefano Diciotti, Silvia Galora, Betti Giusti, Anna Maria Gori, Chiara Marzi, Anna Melone, Damiano Mistri, Francesca Pescini, Giovanni Pracucci, Valentina Rinnoci, Cristina Sarti, Enrico Fainardi, Rossella Marcucci, Emilia Salvadori
Publikováno v:
Medicina, Vol 55, Iss 10, p 626 (2019)
Background and Objectives: In anticoagulated atrial fibrillation (AF) patients, the validity of models recommended for the stratification of the risk ratio between benefits and hemorrhage risk is limited. Cerebral small vessel disease (SVD) represent
Externí odkaz:
https://doaj.org/article/adb7f85d357a4d65bb20e05bb4759d0e
Autor:
Martina Squitieri, Guido Chiti, Valentina Rinnoci, Francesca Pescini, Ida Donnini, Anna Poggesi, Leonardo Pantoni, Emilia Salvadori, Fabio Fierini, Laura Tudisco, Anna Melone
Publikováno v:
Drugs & Aging
Background No approved treatment is available for patients with vascular cognitive impairment (VCI) due to cerebral small vessel disease (SVD). Objective The CONIVaD (Choline Alphoscerate and Nimodipine in Vascular Dementia) study aimed to investigat
Autor:
Wolfgang Löscher, Denise Rageot, Rohitha Sriramaratnam, Erhan Keles, Petra Hillmann, Matthias Hamburger, Andrea Treyer, Doriano Fabbro, Florent Beaufils, Paul Hebeisen, Anna Melone, Matthias P. Wymann, Martina De Pascale, Lukas Bissegger, Chiara Borsari, Thomas Bohnacker
Publikováno v:
Journal of Medicinal Chemistry. 63:13595-13617
The mechanistic target of rapamycin (mTOR) pathway is hyperactivated in cancer and neurological disorders. Rapalogs and mTOR kinase inhibitors (TORKi) have recently been applied to alleviate epileptic seizures in tuberous sclerosis complex (TSC). Her
Autor:
Chiara Borsari, Doriano Fabbro, Petra Hillmann, Florent Beaufils, Thomas Bohnacker, Matthias P. Wymann, Denise Rageot, Ivan Buslov, Erhan Keles, Alexander M. Sele, Anna Melone, Paul Hebeisen
Publikováno v:
ACS Medicinal Chemistry Letters
The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is a critical regulator of cell growth and is frequently hyperactivated in cancer. Therefore, PI3K inhibitors represent a valuable asset in cancer therapy. Herein we
Autor:
Petra Hillmann, Thomas Bohnacker, Matthias P. Wymann, Alix Dall’Asen, Eileen Jackson, Anna Melone, Florent Beaufils, Denise Rageot, Jean-Baptiste Langlois, Alexander M. Sele, Doriano Fabbro, Paul Hebeisen, Chiara Borsari
Publikováno v:
Journal of Medicinal Chemistry. 62:8609-8630
The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin d
Autor:
Denise Rageot, Thomas Bohnacker, Erhan Keles, Jacob A. McPhail, Reece M. Hoffmann, Anna Melone, Chiara Borsari, Rohitha Sriramaratnam, Alexander M. Sele, Florent Beaufils, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, John E. Burke, Matthias P. Wymann
Publikováno v:
Journal of Medicinal Chemistry. 62:6241-6261
Autor:
Chiara, Borsari, Erhan, Keles, Denise, Rageot, Andrea, Treyer, Thomas, Bohnacker, Lukas, Bissegger, Martina, De Pascale, Anna, Melone, Rohitha, Sriramaratnam, Florent, Beaufils, Matthias, Hamburger, Paul, Hebeisen, Wolfgang, Löscher, Doriano, Fabbro, Petra, Hillmann, Matthias P, Wymann
Publikováno v:
Journal of medicinal chemistry. 63(22)
The mechanistic target of rapamycin (mTOR) pathway is hyperactivated in cancer and neurological disorders. Rapalogs and mTOR kinase inhibitors (TORKi) have recently been applied to alleviate epileptic seizures in tuberous sclerosis complex (TSC). Her